ArticleACS nano2015
In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine.
Article in ACS nano, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- A Review of Silica-Based Nanoplatforms for Anticancer Cargo Delivery.International journal of molecular sciences · 2025Review
- Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside.Molecular cancer · 2025Review
- Photothermal Coating on Zinc Alloy for Controlled Biodegradation and Improved Osseointegration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cuproptosis-based layer-by-layer silk fibroin nanoplatform-loaded PD-L1 siRNA combining photothermal and chemodynamic therapy against metastatic breast cancer.Materials today. Bio · 2024Article
- Multifunctional mesoporous silica nanoparticles for biomedical applications.Signal transduction and targeted therapy · 2023Review
- Nanomedicine in cancer therapy.Signal transduction and targeted therapy · 2023Review
- Nanoparticles labeled with gamma-emitting radioisotopes: an attractive approach for in vivo tracking using SPECT imaging.Drug delivery and translational research · 2023Review
- NIR-Absorbing Mesoporous Silica-Coated Copper Sulphide Nanostructures for Light-to-Thermal Energy Conversion.Nanomaterials (Basel, Switzerland) · 2022Article
- Applications and Biocompatibility of Mesoporous Silica Nanocarriers in the Field of Medicine.Frontiers in pharmacology · 2022Review
- Photothermal effects of CuS-BSA nanoparticles on H22 hepatoma-bearing mice.Frontiers in pharmacology · 2022Article
- Near-infrared light triggered activation of pro-drug combination cancer therapy and induction of immunogenic cell death.International journal of pharmaceutics · 2021Article
- Ultrasmall Porous Silica Nanoparticles with Enhanced Pharmacokinetics for Cancer Theranostics.Nano letters · 2021Article
- The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.Chemical reviews · 2021Review
- A new pH/NIR responsive theranostic agent for magnetic resonance imaging guided synergistic therapy.RSC advances · 2021Article
- Current Stimuli-Responsive Mesoporous Silica Nanoparticles for Cancer Therapy.Pharmaceutics · 2021Review
- The Coppery Age: Copper (Cu)-Involved Nanotheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Animal heat activated cancer therapy by a traditional catalyst TiOScientific reports · 2020Article
- Dual-targeted photothermal agents for enhanced cancer therapy.Chemical science · 2020Review
- A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies.Frontiers in chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Actively targeted theranostic nanomedicine may be the key for future personalized cancer management. Although numerous types of theranostic nanoparticles have been developed in the past decade for cancer treatment, challenges still exist in the engineering of biocompatible theranostic nanoparticles with highly specific in vivo tumor targeting capabilities. Here, we report the design, synthesis, surface engineering, and in vivo active vasculature targeting of a new category of theranostic nanoparticle for future cancer management. Water-soluble photothermally sensitive copper sulfide nanoparticles were encapsulated in biocompatible mesoporous silica shells, followed by multistep surface engineering to form the final theranostic nanoparticles. Systematic in vitro targeting, an in vivo long-term toxicity study, photothermal ablation evaluation, in vivo vasculature targeted imaging, biodistribution and histology studies were performed to fully explore the potential of as-developed new theranostic nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.